Phuong Khanh Morrow - 23 May 2023 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
25 May 2023, 17:35:47 UTC
Prior SEC filing
14 Mar 2023
Next SEC filing
17 Oct 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact

Key filing fact

Phuong Khanh Morrow filed Form 4 for CRISPR Therapeutics AG (CRSP) on 25 May 2023.

Key facts

  • This page summarizes Phuong Khanh Morrow's Form 4 filing for CRISPR Therapeutics AG (CRSP).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 25 May 2023, 17:35.

Change

  • Previous filing in this sequence was filed on 14 Mar 2023.
  • Current net transaction value: -$166,555.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRSP transaction

Common Shares

Options Exercise

Transaction value
Shares
+6,938
Change %
Price
Shares after
6,938
Date
23 May 2023
Ownership
Direct
Footnotes
F1, F2
CRSP transaction

Common Shares

Tax liability

Transaction value
$166,555
Shares
-2,527
Change %
-36%
Price
$65.91
Shares after
4,411
Date
24 May 2023
Ownership
Direct
Footnotes
F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
+6,938
Change %
+50%
Price
Shares after
20,812
Date
23 May 2023
Ownership
Direct
Underlying class
Common Shares
Underlying amount
6,938
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The restriced stock units shall vest as follows: (i) one quarter of the shares shall vest on May 23, 2023, (ii) one quarter of the shares shall vest on May 23, 2024, (iii) one quarter of the shares shall vest on May 23, 2025, and (iv) one quarter of the shares shall vest on May 23, 2026.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Footnote F3

On May 23, 2022, the reporting person was granted 27,750 restricted stock units. On May 23, 2023, 6,938 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .